Overcoming targeted protein degraders biggest challenge

David O’Connell, director of scientific affairs at PCI Pharma Services, explores how enabling technologies are helping targeted protein degraders (TPDs) overcome their biggest challenge. 

Nothing vast enters the realm of mortals without a curse. Targeted protein degraders (TPDs) are a case in point. As one of the fastest-growing frontiers in oral solid dose development, these molecules hold great therapeutic promise, yet their delivery challenges remain formidable. 

First described in the early 2000s, TPDs – including proteolysis-targeting chimeras (PROTACs) and…